Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Gross Margin % is 91.07% as of Mar. 2026, which is 2% below its 10-year median of 92.71. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 95.34% on this metric.
The historical rank and industry rank for Invicta Diagnostic's Gross Margin % or its related term are showing as below:
NSE:INVICTA'
s Gross Margin % Range Over the Past 10 Years
Min: 91.58 Med: 92.71 Max: 92.94
Current: 91.58
During the past 3 years, the highestGross Margin % of Invicta Diagnostic was 92.94%. The lowest was 91.58%. And the median was 92.71%.
NSE:INVICTA's Gross Margin % is ranked better than 95.34% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.76
vs NSE:INVICTA: 91.58
Invicta Diagnostic had a gross margin of 91.07% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Invicta Diagnostic was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Invicta Diagnostic had a gross margin of 91.07% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Invicta Diagnostic Gross Margin % Related Terms
Invicta Diagnostic Gross Margin % Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Gross Margin % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Gross Margin %
92.94
92.71
91.58
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Gross Margin %
0.00
0.00
92.04
91.07
NSE:INVICTA vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Invicta Diagnostic (NSE:INVICTA) has a Gross Margin % of 91.07% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Invicta Diagnostic and its competitors. This is near median its historical median of 92.71. Over the past decade, Invicta Diagnostic's Gross Margin % has ranged from 91.58 to 92.94. According to the industry distribution chart, Invicta Diagnostic ranks #9 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 4.7%.
Is Invicta Diagnostic's Gross Margin % too high?
Invicta Diagnostic's current Gross Margin % of 91.07% is near median its 10-year median of 92.71. Over the past 10 years, this metric has ranged from a low of 91.58 to a high of 92.94. The Medical Diagnostics & Research industry median Gross Margin % is 50.76. Invicta Diagnostic's value of 91.07% is 79.4% above this industry median. Based on the distribution chart, Invicta Diagnostic ranks #9 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #9 out of 193 companies for Gross Margin %. This places Invicta Diagnostic in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.76. Invicta Diagnostic's value of 91.07% is 79.4% above this benchmark. Historically, Invicta Diagnostic's own Gross Margin % has ranged from 91.58 to 92.94 over the past decade. While the company's 10-year median is 92.71 vs. the industry median of 50.76, Invicta Diagnostic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.76, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current Gross Margin % of 91.07% is 79.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Gross Margin % is 91.07%, which is near median its own 10-year median of 92.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Gross Margin % of 91.07%. The current Gross Margin % is 91.07%, which is near median its 10-year median of 92.71 and 79.4% above the Medical Diagnostics & Research industry median of 50.76. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Gross Margin % is 91.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
